Skin barrier dysfunction, a defining feature of atopic dermatitis (AD), arises from multiple
interacting systems. In AD, skin inflammation is caused by host–environment interactions …

Atopic dermatitis (AD) is the most common chronic inflammatory skin disease. Genetic
predisposition, epidermal barrier disruption, and dysregulation of the immune system are …

Background Tralokinumab, a fully human monoclonal antibody, specifically neutralizes
interleukin‐13, a key cytokine driving peripheral inflammation in atopic dermatitis (AD). In …

Background Dupilumab is an IL-4 receptor α mAb inhibiting signaling of IL-4 and IL-13, key
drivers of type 2–driven inflammation, as demonstrated by its efficacy in patients with …

Atopic dermatitis (AD) is a common inflammatory skin condition that has traditionally been
considered a paradigmatic type 2 immunity (T2)‐driven disease. Interleukin (IL)‐4 and IL‐13 …

One of the fundamental issues in the microbiome research is characterization of the healthy
human microbiota. Recent studies have elucidated substantial divergences in the …

The pathogenesis of psoriasis can be explained by dysregulation of immunological cell
function as well as keratinocyte proliferation/differentiation. Recently, the immunological …

Atopic dermatitis (AD), the most common chronic inflammatory skin disease, is driven by
both terminal keratinocyte differentiation defects and strong type 2 immune responses. In …

Host defence peptides (HDPs) are short, cationic amphipathic peptides with diverse
sequences that are produced by various cells and tissues in all complex life forms. HDPs …

Background IL-13 has an important role in atopic dermatitis (AD) pathogenesis.
Tralokinumab is a fully human mAb that potently and specifically neutralizes IL-13. Objective …